Fresh insights, bold science, and global momentum—this edition delivers a snapshot of the early-phase clinical trial landscape across Latin America and Australia. From regulatory moves to first-in-human milestones, here’s what’s shaping the future of Medtech and Biopharma research:
first-in-human · clinical trial · regulatory · gene therapy · FDA · MedTech
Fresh insights, bold science, and global momentum—this edition delivers a snapshot of the early-phase clinical trial landscape across U.S. regulatory anchoring plus U.S. and Latin America execution. From regulatory moves to first-in-human milestones, here’s what’s shaping the future of Medtech and Biopharma research:
Explore what’s new—and what it means for your next study.
Waskyra (etuvetidigene autotemcel) is now the first FDA-approved gene therapy for Wiskott-Aldrich Syndrome (WAS)—a rare, inherited immune disorder affecting both children and adults. The therapy uses the patient’s own blood stem cells, genetically modified to correct the underlying mutation that causes WAS.
Clinical data from two multinational trials and an expanded access program showed a 93% reduction in severe infections and 60% fewer severe bleeding events within one year after treatment. For patients lacking a matched stem cell donor, Waskyra offers a new curative pathway.
ViroMissile has launched a Phase I trial for IDOV-Immune, an intravenously delivered oncolytic virus designed to target and destroy advanced solid tumors while activating the immune system. The trial, which dosed its first patient in Australia, will assess safety, immune response, and early antitumor activity in up to 78 participants.
Why It Matters: This trial introduces a single-dose, systemically administered virotherapy that could broaden access to immuno-oncology treatments—particularly in settings where localized delivery isn’t practical. Australia’s early involvement also reinforces its position as a growing hub for first-in-human oncology research.
Romania is emerging as a smart choice for early-phase clinical trials in Eastern Europe—but navigating its regulatory gateway, the NAMMD pathway, requires precision, planning, and local insight.
Sponsors must prepare bilingual submissions, align with both EU and national regulations, and clear ethics and compliance reviews before study launch. Approval timelines range from 30–60 days, but early preparation can prevent costly delays. The upside? Access to high-quality investigators, a growing pool of trial-ready sites, and a cost-competitive environment.
Does your company need accelerated first-in-human clinical trial results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule your first-in-human trial consultation.
Amylyx Pharmaceuticals has released cohort 1 safety and tolerability results from its first-in-human LUMINA trial evaluating AMX0114, an investigational antisense oligonucleotide targeting calpain-2 in people with ALS. The treatment was generally well tolerated with no drug-related serious adverse events, supporting progression to a second cohort. The multinational Phase I study is also assessing biomarkers of neurodegeneration, including neurofilament light chain (NfL) levels.
Bottom line: With FDA Fast Track designation, a novel mechanism of action, and a clear safety profile in early-stage participants, AMX0114 is shaping up to be a key candidate in the pursuit of disease-modifying therapies for ALS.
The FDA has cleared LumosityRx, a prescription digital therapeutic (PDT) by Lumos Labs, designed to improve attention in adults with ADHD. Intended for use alongside medication or therapy, this mobile app delivers 13 clinically validated cognitive training games targeting sustained and selective attention.
Key highlights:
Source: Medical Device Network
Pfizer has signed a global licensing agreement with YaoPharma for YP05002, an oral GLP-1 receptor agonist currently in Phase 1 trials for chronic weight management. The deal includes a $150 million upfront payment and up to $1.94 billion in potential milestone payouts, giving Pfizer full development and commercialization rights after Phase 1.
The move strengthens Pfizer’s presence in the cardiometabolic space, with plans to initiate combination studies alongside existing pipeline assets. As the obesity drug market shifts toward oral therapies, YP05002 positions Pfizer to compete in a growing, high-demand category.
Strategic signal: Early investment in small-molecule GLP-1 therapies reflects a push for more scalable, accessible obesity treatments—and underscores the importance of early-stage partnerships in shaping global pipelines.
← All Global Trial Accelerators editions · Contact bioaccess®